‘A New Benchmark’ Treatment Option for Older Patients with Mantle Cell Lymphoma
June 3rd 2022Adding Imbruvica to a standard-of-care chemotherapy-immunotherapy treatment regimen was associated with a significant improvement in survival in older patients with newly diagnosed mantle cell lymphoma.
Read More
Telehealth Use for Cancer Care Surged During COVID-19, But Inequalities Remain
May 27th 2022An analysis of more than 25,000 patients with one of the more than 20 common cancers identified that even though telehealth use for cancer care increased during the COVID-19 pandemic, certain people were less likely to benefit from the easy access to care.
Read More
Novel Therapy Shows Promise in Group of Patients with Metastatic Colon Cancer
June 7th 2021Responses to the study drug, according to one of the study’s authors, appeared far superior than what would have been expected with other treatments in patients with HER2-expressing metastatic colorectal cancer.
Read More
Imfinzi May Contribute to Long-Term Survival Improvements in Unresectable Non-Small Cell Lung Cancer
June 7th 2021The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.
Read More
Abecma Continues to Improve Survival in Heavily Pretreated Patients With Multiple Myeloma
June 6th 2021After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.
Read More
Lenvima-Keytruda Combination May Show ‘Promising Antitumor Activity’ in Advanced Colorectal Cancer
June 6th 2021More than half of patients with previously treated advanced colorectal cancer who were treated with Lenvima and Keytruda were alive at six months while maintaining a manageable safety profile.
Read More
Novel Drug-Chemo Combo Significantly Improves Survival in Rare Form of Head and Neck Cancer
June 5th 2021The addition of a novel drug to the chemotherapies gemcitabine and cisplatin significantly improved a survival outcome in patients with a rare form of head and neck cancer, compared with chemotherapy alone.
Read More